Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NUVO
Upturn stock ratingUpturn stock rating

Holdco Nuvo Group D.G Ltd. Ordinary Shares (NUVO)

Upturn stock ratingUpturn stock rating
$0.01
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/24/2024: NUVO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Year Target Price $0

Year Target Price $0

Analyst’s Price TargetsFor last 52 week
$0Target price
Low$0
Current$0.01
high$1.23

Analysis of Past Performance

Type Stock
Historic Profit 5.02%
Avg. Invested days 142
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/24/2024

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.65M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -0.41
52 Weeks Range 0.00 - 1.23
Updated Date 06/29/2025
52 Weeks Range 0.00 - 1.23
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.01

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -17524.49%

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 39531120
Price to Sales(TTM) 0.7
Enterprise Value 39531120
Price to Sales(TTM) 0.7
Enterprise Value to Revenue 63.33
Enterprise Value to EBITDA -
Shares Outstanding 33261500
Shares Floating 9927622
Shares Outstanding 33261500
Shares Floating 9927622
Percent Insiders 39.62
Percent Institutions 1.44

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Holdco Nuvo Group D.G Ltd. Ordinary Shares

stock logo

Company Overview

overview logo History and Background

Holdco Nuvo Group D.G Ltd. Ordinary Shares, operating under the symbol NVRO, primarily focuses on medical solutions for women's health. They are known for their Invu by Nuvo system, a remote pregnancy monitoring system. Its history includes research and development in ultrasound technology and commercialization of its innovative monitoring solution.

business area logo Core Business Areas

  • Remote Pregnancy Monitoring: Develops and markets Invu by Nuvo, a remote fetal monitoring system, aiming to improve prenatal care access and quality. It allows physicians to monitor maternal and fetal heart rates remotely.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in medical devices and technology. The organizational structure likely involves R&D, marketing, sales, and regulatory affairs departments focused on the Invu system and related technologies.

Top Products and Market Share

overview logo Key Offerings

  • Invu by Nuvo: A remote pregnancy monitoring system that provides continuous maternal and fetal heart rate monitoring. Its competitors include traditional fetal monitoring devices and other emerging remote monitoring solutions. Market share is still developing as remote monitoring becomes more widely adopted.

Market Dynamics

industry overview logo Industry Overview

The medical device industry, particularly in prenatal care, is experiencing growth driven by technological advancements, increasing maternal age, and a need for improved prenatal care accessibility. The demand for remote monitoring solutions is growing due to convenience and improved data access.

Positioning

Nuvo Group is positioned as an innovator in remote pregnancy monitoring with its Invu system. Its competitive advantage lies in its non-invasive, continuous monitoring capability and user-friendly design.

Total Addressable Market (TAM)

The TAM for remote pregnancy monitoring is estimated in the billions of dollars, globally. Nuvo is positioned to capture a portion of this market as adoption increases.

Upturn SWOT Analysis

Strengths

  • Innovative remote monitoring technology
  • FDA clearance for Invu system
  • Potential to improve prenatal care access
  • Proprietary technology

Weaknesses

  • Limited market presence
  • Reliance on a single product
  • Need for reimbursement coverage
  • Cash burn rate

Opportunities

  • Expanding remote monitoring market
  • Partnerships with healthcare providers
  • Increased adoption of telehealth
  • Potential for international expansion

Threats

  • Competition from established medical device companies
  • Regulatory hurdles
  • Reimbursement challenges
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • GE Healthcare (GE)
  • Philips (PHG)
  • Siemens Healthineers (SMMNY)

Competitive Landscape

Compared to established players like GE and Philips, Nuvo Group faces challenges in terms of market reach and brand recognition. However, it benefits from its focus on remote pregnancy monitoring and innovative technology.

Growth Trajectory and Initiatives

Historical Growth: Limited history as a publicly traded company to show historical growth. Growth depends on the commercial success of Invu.

Future Projections: Future projections are dependent on market acceptance of Invu, regulatory approvals, and reimbursement coverage. Analyst estimates would be crucial for providing specific growth projections.

Recent Initiatives: Recent initiatives likely include expanding sales and marketing efforts, securing reimbursement coverage, and conducting clinical trials to support Invu's effectiveness.

Summary

Nuvo Group, with its Invu system, shows promise in the remote pregnancy monitoring sector, but the company is still relatively small and carries notable financial risks. Key aspects to monitor are sales growth, adoption of reimbursement, expansion of strategic partnerships, and clinical data from ongoing and future trials.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Industry Reports
  • Analyst Estimates (where available)

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. Future performance is not guaranteed.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Holdco Nuvo Group D.G Ltd. Ordinary Shares

Exchange NYSE MKT
Headquaters -
IPO Launch date 2024-05-01
CEO & Director Mr. Robert Maurice Powell Jr.
Sector Healthcare
Industry Medical Devices
Full time employees -
Full time employees -

Holdco Nuvo Group D.G Ltd engages in the research, development, and marketing of medical devices for pregnancy monitoring in Israel, the United States, and internationally. It provides INVU platform, a remote pregnancy monitoring platform that provides expectant mothers with a self -administered wireless sensory band, which enables them and their obstetricians to monitor maternal and fetal heart rate, and maternal uterine activity at home and in the clinic from the 32nd week of pregnancy until the beginning of labor. The company's INVU platform includes a wireless sensory band with multi-modality technology to capture signals to enable the INVU platform; and a cloud computing environment that processes and analyzes data and transmits personalized reports on maternal and fetal health metrics to the expectant mother and her obstetrician through digital visualization tools. It has a collaboration with Royal Philips and Charité " Universitätsmedizin Berlin. The company was formerly known as Nuvo Group Ltd. and changed its name to Holdco Nuvo Group D.G Ltd in May 2024. Holdco Nuvo Group D.G Ltd incorporated in 2006 and is headquartered in Tel Aviv, Israel. On August 22, 2024, Holdco Nuvo Group D.G Ltd filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.